Significant reductions from baseline to the final on-treatment assessment on the oppositional subscale of the CPRS-R : L were seen with GXR plus psychostimulant compared with placebo plus psychostimulant , both in the overall study population ( placebo-adjusted least squares -LSB- LS -RSB- mean change from baseline to the final on-treatment assessment : GXR a.m. + psychostimulant , -@ , p = @ ; GXR p.m. + psychostimulant , -@ , p = @ ) as well as in the subgroup of subjects with significant baseline oppositional symptoms ( GXR a.m. + psychostimulant , -@ , p = @ ; GXR p.m. + psychostimulant , -@ , p = @ ) .